For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Vyndamax and Attruby represents a significant breakthrough . These novel therapies protect the transthyretin protein, preventing its destructive build-up and lessening the impact of the illness. Individuals are now experiencing bene